RECURSION PHARMACEUTICALS-A (RXRX) Stock News
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
RXRX Latest News, Press Relases and Analysis
Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now
We recently published a list of the 13 Best Artificial Intelligence Stocks Under $50 to Buy Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other AI stocks under $50. On May 8, Dan Ives of Wedbush Securities joined CNBC’s ‘Squawk on the Street’ to […]
Mentions: RACE
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
This could upend an already shaky stock market. The recent market downturn is an excellent example. After the election, the general consensus was that the new administration would be positive for the stock market, and the major indexes rose immediately after Election Day.
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Artificial intelligence (AI) is the defining technological innovation of our age. The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity.
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Mentions: OKLO
‘We live modestly’: My wife and I have $900K in stocks and $380K in savings and CDs. Are we holding too much cash?
“My investment adviser says we have too much invested in cash instruments.”
As talk about taxing the rich heats up, here are 7 ways millionaires stay wealthy that can help you too
How to keep money flowing in — no matter what life throws at you.
‘I’m flabbergasted’: My friend wants to borrow $5,800 to save his home from foreclosure. What should I do?
“I previously loaned a friend $7,000, and she later died.”
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. Recursion revealed disappointing first-quarter earnings on Monday and announced it would pare down its development pipeline.
Why SolarEdge Technologies Stock Is Shining Today
Shares of SolarEdge Technologies (NASDAQ: SEDG) caught a welcome ray of sunlight on Tuesday. The maker of power management systems used in solar power installations crushed Wall Street's expectations in this morning's first-quarter report.
Recursion axes drug programmes to streamline pipeline
Recursion is streamlining its portfolio in the wake of its 2024 merger with Exscientia.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Recursion to Participate in Upcoming Investor Conferences
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
It continues to draw limited revenue, while its costs are growing notably. Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. For the quarter, Recursion -- which although a clinical-stage company earns some coin from collaboration agreements with large pharmaceutical companies -- booked just over $14.7 million in revenue.
AI specialist Recursion trims pipeline in latest shakeup
The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors.
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in...
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data
Traders flagged a key technical level at $4.65 and raised concerns over an outlier patient in the Tupelo trial, with attention now turning to management’s commentary during the earnings call.
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data...
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
3 No-Brainer Warren Buffett Stocks to Buy Right Now
American Express has a closed-loop model that makes money under varying conditions. Coca-Cola is one of the highest-yielding Dividend Kings you can buy. Investors look to Warren Buffett for advice in any market, but listening to his wisdom can help people get through tough times, like today's market, with calm and clarity.
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other stocks that Jim Cramer discussed. During a recent Mad Money episode, Jim Cramer discussed how President Donald Trump’s influence shapes the […]
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT...
2 Stocks Down 52% and 30% to Buy Right Now
The stock market has been under pressure in 2025. Meanwhile, the more growth-oriented Nasdaq Composite index is down approximately 13.5% across that stretch. With that in mind, read on to see why two Motley Fool contributors think these stocks are good buys after big valuation pullbacks in 2025.
3 Monster Stocks to Hold for the Next 10 Years
They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically...
S&P 500 Bounce Has Traders Fearing Another Head-Fake Market
(Bloomberg) -- Wall Street pros have a warning for investors eager to jump back into the stock market as it rebounds Tuesday: Watch out for headfakes in the middle of a longer-term decline.Most Read from BloombergTrump Gives New York ‘One Last Chance’ to End Congestion FeeDOGE Visits National Gallery of Art to Discuss Museum’s Legal StatusThe Racial Wealth Gap Is Not Just About Money“We call it the ‘pull the football’ market,” said Joe Saluzzi, co-manager of trading at Themis Trading, referring
Rich Dad Poor Dad author picks a new favorite asset
Robert Kiyosaki calls silver the best deal in today's market—even though he owns gold and Bitcoin.
Chart Industries, Inc. (GTLS): A Bull Case Theory
We came across a bullish thesis on Chart Industries, Inc. (GTLS) on Twitter by LTVresearch. In this article, we will summarize the bulls’ thesis on GTLS. Chart Industries, Inc. (GTLS)’s share was trading at $128.45 as of April 17th. GTLS’s trailing and forward P/E were 30.80 and 10.91 respectively according to Yahoo Finance. Chart Industries (GTLS) presents […]